CDMO Market Insight, Pricing and Benchmarking Reports

NICE INSIGHT REPORT

Messenger Ribonucleic Acid, mRNA:Market Insight, CDMO Pricing and Competitor Benchmarking

Updated Monthly

2025 mRNA manufacturing pricing study—the first of its kind
Survey of clinical trials currently being conducted, segmented by type and treatment
SME analysis and forecasts of biotech fundraising
Over 65 CDMO profiles, including mRNA, chemically synthesized RNA and LNP manufacturers
mRNA vaccines and therapeutic manufacturing challenges and innovations

Preview Report Contact Sales

Key market insights for innovators, CDMOs and investors in the mRNA industry.

Essential price benchmarking and market intelligence for CDMOs

Compare prices to your competitors with our strategic pricing study, which breaks down the manufacturing process and industry costs. As investments pour in from both the private and government sectors, learn from leaders in mRNA-based drugs so you can better position your business.

Grasp the mRNA Vaccine & Therapeutics Pipeline

Our Market Analysis provides an in-depth R&D pipeline report segmented by indication and development stage. Make informed business decisions with our guide to approved mRNA drugs and the developmental and clinical landscape. See where your competitors are from pre-clinical through Phase III trials.

Our Market Analysis combines data insights and interviews with prominent mRNA players so your sales team can unlock the booming industry.

Preview Report Contact Sales

The Messenger Ribonucleic Acid, mRNA: Market Insight, CDMO Pricing and Competitor Benchmarking provides

/hubfs/2024%20Reports/03_mRNA/01%20pricing%20data%20icon%2065x65@2x.png

Strategic pricing study that analyzes the manufacturing process and primary data

/hubfs/2024%20Reports/03_mRNA/02%20profiles%20icon%2065x65@2x.png

Over 65 CDMO profiles which include segment, proprietary technologies and location

/hubfs/2024%20Reports/03_mRNA/03%20pie%20chart%20icon%2065x65@2x.png

Market intelligence segmented by drug type and disease application

/hubfs/2024%20Reports/03_mRNA/04%20pipeline%20icon%2065x65@2x.png

Pipeline development mapping for approved mRNA drugs and preclinical through phase III trials

/hubfs/2024%20Reports/03_mRNA/05%20data%20analytics%20icon%2065x65@2x.png

Investor insights for one of the fastest growing markets in pharma

/hubfs/2024%20Reports/03_mRNA/06%20benefits%20icon%2065x65@2x.png

Unique benefits and complexities to mRNA manufacturing that is invaluable to developers

Over 900 hours of data collection and analysis

with invaluable insights from industry experts